Specifically, the company said that it will share data from in situ single-cell transcriptomic imaging in formalin-fixed paraffin-embedded tissue sections using Merscope.

In addition, the company will present a poster presentation on how a spatially resolved map of colorectal cancer can best identify novel spatial relationships between cancer cells and the microenvironment, it said. The work was conducted with Massachusetts General Hospital.

Vizgen makes single-cell spatial genomics platform available across U.S.
Vizgen's Merscope, a spatial genomics platform, is now broadly available across the U.S. Additionally, Vizgen released its second open-access dataset,...

Vizgen begins shipping Merscope instruments for single-cell genomics
Vizgen has shipped its first commercial Merscope instruments to research institutions as part of a limited summer release program. Merscope enables high-plex,...

Vizgen raises $37M to bring Merscope platform to market
Vizgen has closed $37 million in financing to support the commercialization and manufacturing of its Merscope platform.

Vizgen launches integrated Merscope in situ imaging platform
Vizgen has launched its Merscope platform, a multiplexed, error-robust, single-cell in situ transcriptomic imaging technology.

Vizgen debuts accelerator lab in the U.S.
Life sciences company Vizgen has established an accelerator lab in the U.S. to advance pharmaceutical research and development.